Preferred Label : medrogestone;

MeSH definition : 6,17-Dimethylpregna-4,6-diene-3,20-dione. A synthetic progestational hormone with actions similar to those of progesterone. It is used in the treatment of menstrual irregularities and has also been employed in the treatment of prostatic hypertrophy and endometrial carcinoma.;

CISMeF synonym : wyeth brand of medrogestone; medrogestone wyeth brand; solvay brand of medrogestone; medrogestone solvay brand; biodim brand of medrogestone; medrogestone biodim brand;

MeSH hyponym : colpro; colprone; prothil;

MeSH CAS label : Pregna-4,6-diene-3,20-dione, 6,17-dimethyl-;

MeSH Related Number : 977-79-7 (Medrogestone);

Registry Number MeSH : 977-79-7;

MeSH annotation : a synthetic progestational hormone;

Wikipedia link : https://en.wikipedia.org/wiki/Colpro;

Codes EINECS : 213-555-0;

Is substance : O;

UNII : 077DN93G5B;

InChIKey : HCFSGRMEEXUOSS-JXEXPEPMSA-N;

Details


Main resources

You can consult :

6,17-Dimethylpregna-4,6-diene-3,20-dione. A synthetic progestational hormone with actions similar to those of progesterone. It is used in the treatment of menstrual irregularities and has also been employed in the treatment of prostatic hypertrophy and endometrial carcinoma.

https://www.has-sante.fr/jcms/p_3588262/fr/colprone-medrogestone-gynecologie
2025
false
false
false
France
evaluation of the transparency committee
medrogestone
gynecology
colprone

---
https://ansm.sante.fr/informations-de-securite/nouvelles-conditions-de-prescription-et-de-delivrance-des-specialites-a-base-dacetate-de-medroxyprogesterone-depo-provera-150-mg-3-ml-et-de-medrogestone-colprone-5-mg-liees-au-risque-de-meningiome-a-compter-du-1er-juillet-2024
2024
false
false
false
France
French
guidelines for drug use
meningioma
risk management
legislation, drug
medroxyprogesterone acetate
Drug-Related side effects and adverse reactions
medrogestone
progesterone congeners
medrogestone
medroxyprogesterone
drug prescriptions
Renewal of prescription (procedure)
professional role
physicians
pharmacists
summary of product characteristics
package leaflet

---
https://ansm.sante.fr/tableau-marr/medrogestone
2024
false
false
false
France
French
risk management
medrogestone
administration, oral
medrogestone
risk
meningioma
continuity of patient care
progesterone congeners
patients guideline
drug information
meningioma

---
https://ansm.sante.fr/actualites/progestatifs-et-risque-de-meningiome-renforcement-des-conditions-de-prescription-et-de-delivrance-de-depo-provera-150-mg-3-ml-et-colprone-5-mg
2024
false
false
false
France
French
guidelines for drug use
meningioma
risk management
legislation, drug
medroxyprogesterone acetate
Drug-Related side effects and adverse reactions
medrogestone
progesterone congeners
medrogestone
medroxyprogesterone

---
https://ansm.sante.fr/actualites/progestatifs-et-risque-de-meningiome-recommandations-pour-limiter-ce-risque
2023
false
false
false
France
French
guideline
guidelines for drug use
medrogestone
medrogestone
meningioma
Drug-Related side effects and adverse reactions
medroxyprogesterone acetate
medroxyprogesterone acetate
progestins
progestins
continuity of patient care
patient safety
promegestone
risk management
risk factors

---
http://www.has-sante.fr/portail/jcms/c_2608651/fr/colprone
http://www.has-sante.fr/portail/jcms/c_748309/colprone
2016
false
France
French
premenopause
progesterone
treatment outcome
medrogestone
progesterone congeners
administration, oral
insurance, health, reimbursement
medrogestone
evaluation of the transparency committee

---
http://www.lecrat.eu/?s=M%C3%A9drogestone
2013
France
French
drug information
pregnancy
medrogestone
antineoplastic agents, hormonal
breast feeding
medrogestone

---
Nous contacter.
26/04/2025


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.